The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The modified risk stratification of WM: integrating older age, abnormal LDH, and low albumin
Patrizia Mondello, MD, PhD, Mayo Clinic, Rochester, MN, discusses the modified staging system for Waldenström’s macroglobulinemia (WM) and how it is used to risk stratify patients. She mentions three key prognostic factors—older age, abnormal lactate dehydrogenase (LDH), and low albumin—that were integrated into the current classification to better predict patient outcomes. This interview took place at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
